静脉与口服氨甲环酸在减少胸腰椎融合术失血方面等效:一项前瞻性随机试验
该前瞻性随机试验纳入83例择期后路胸腰椎融合术患者,比较术前2小时口服氨甲环酸1.95g与术中静脉氨甲环酸2g(切皮前1g、关创前1g)的围手术期失血。结果显示两组血红蛋白下降、计算失血量等效,输血率和深静脉血栓/肺栓塞发生率无显著差异。作者认为口服氨甲环酸因成本较低可作为静脉氨甲环酸的替代选择。
要点
- 静脉与口服氨甲环酸组血红蛋白平均下降分别为3.36 g/dL与3.43 g/dL,等效(P=0.01)。
- 两组计算失血量分别为1235 mL与1312 mL,等效(P=0.02)。
- 输血率静脉组19%(8例) vs 口服组13%(5例),无显著差异(P=0.44)。
核心结论
- 择期后路胸腰椎融合术患者接受静脉或口服氨甲环酸后的围手术期失血量相同。
- 作者认为,鉴于口服氨甲环酸成本较低,可作为静脉氨甲环酸的优良替代选择,并可能改善所研究人群的医疗成本效益。
研究设计与样本
- 前瞻性随机试验,纳入2017年2月至12月在一所大学附属三级医疗中心入组的患者。
- 83例接受胸腰椎融合术的患者随机接受术前2小时口服氨甲环酸1.95 g或术中静脉氨甲环酸2 g(切皮前1 g、关创前1 g)。
- 样本按融合节段数进一步分层为1-2节段、3-5节段和>5节段三类。
- 主要结局为血红蛋白下降;次要结局包括计算失血量、引流量、术后输血、并发症和住院时长。
- 采用双单侧检验(TOST)进行等效性分析,P值<0.05提示等效。
主要发现
- 43例接受静脉氨甲环酸,40例接受口服氨甲环酸。
- 除体质指数(BMI)外,两组患者人口学因素相似。
- 静脉组与口服组血红蛋白平均下降分别为3.36 g/dL vs 3.43 g/dL(P=0.01,等效)。
- 静脉组与口服组计算失血量分别为1235 mL vs 1312 mL(P=0.02,等效)。
- 静脉组8例(19%)接受输血,口服组5例(13%)接受输血(P=0.44);每组各1例发生深静脉血栓/肺栓塞(静脉组2%、口服组3%,P=0.96)。
关键数值与推荐
- 等效性判断标准:双单侧检验P值<0.05提示等效。
- 血红蛋白下降:静脉组3.36 g/dL vs 口服组3.43 g/dL(P=0.01,等效)。
- 计算失血量:静脉组1235 mL vs 口服组1312 mL(P=0.02,等效)。
- 输血率:静脉组19%(8例) vs 口服组13%(5例)(P=0.44)。
- 深静脉血栓/肺栓塞:静脉组2%(1例) vs 口服组3%(1例)(P=0.96)。
临床怎么用
- 作者认为,口服氨甲环酸可作为静脉氨甲环酸的优良替代选择,用于择期后路胸腰椎融合术患者,因其成本较低并可能改善医疗成本效益。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
STUDY DESIGN: A prospective randomized trial of patients enrolled at a university affiliated tertiary medical center between February and December 2017. OBJECTIVE: To compare perioperative blood loss in patients undergoing elective posterior thoracolumbar fusion who were treated with intravenous (IV) versus oral (PO) tranexamic acid (TXA). SUMMARY OF BACKGROUND DATA: The use of antifibrinolytic agents such as TXA to decrease operative blood loss and allogenic blood transfusions is well documented in the literature. While evidence supports the use of IV and topical formulations of TXA in spine surgery, the use of PO TXA has not been studied. METHODS: Eighty-three patients undergoing thoracolumbar fusion were randomized to receive 1.95 g of PO TXA 2 hours preoperatively or 2 g IV TXA (1 g before incision and 1 g before wound closure) intraoperatively. The sample was further stratified into three categories based on number of levels fused (1-2 level fusions, 3-5, and >5). The primary outcome was the reduction of hemoglobin. Secondary outcomes included calculated blood loss, drain output, postoperative transfusion, complications, and length of hospital stay. Equivalence analysis was performed with a two one-sided test (TOST). A P-value of <0.05 suggested equivalence between treatments. RESULTS: Fourty three patients received IV TXA and 40 patients received PO TXA. Patient demographic factors were similar between groups except for body mass index (BMI). The mean reduction of hemoglobin was similar between IV and PO groups (3.36 g/dL vs. 3.43 g/dL, respectively; P = 0.01, equivalence). Similarly, the calculated blood loss was equivalent (1235 mL vs. 1312 mL, respectively; P = 0.02, equivalence). Eight patients (19%) in IV TXA group received a transfusion compared with five patients in PO TXA group (13%) (P = 0.44). One patient (2% and 3% in IV and PO, respectively) in each group experienced a deep venous thrombosis/pulmonary embolism (P = 0.96). CONCLUSION: Patients treated with IV and PO TXA experienced the same perioperative blood loss after spinal fusions. Given its lower cost, PO TXA represents an excellent alternative to IV TXA in patients undergoing elective posterior thoracolumbar fusion and may improve healthcare cost-efficiency in the studied population. LEVEL OF EVIDENCE: 1.
引用
- Yu CC, Kadri O, Kadado A, et al. Intravenous and Oral Tranexamic Acid Are Equivalent at Reducing Blood Loss in Thoracolumbar Spinal Fusion: A Prospective Randomized Trial. Spine (Phila Pa 1976). 2019. PMID: 30540715. doi:10.1097/BRS.0000000000002954
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。